Novel agents for the treatment of Hodgkin lymphoma

Expert Review of Hematology

Volumn 8, Issue 5, 2015, Pages 659-667

  Dumaswala, Komal ^a   Mehta, Amitkumar ^b  

^a SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^b and Clinical Center   (United States)

Author keywords

brentuximab vedotin; check point inhibitors; Hodgkin lymphoma; Janus kinase inhibitors; nivolumba; pembrolizumab; phosphatidyl inositide 3 kinase inhibitors

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARMUSTINE; CD30 ANTIGEN; CHLORMETHINE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; IPILIMUMAB; JANUS KINASE; LENALIDOMIDE; MELPHALAN; NIVOLUMAB; PANOBINOSTAT; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); HODGKIN DISEASE; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84941196576     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2015.1081562     Document Type: Review

References (70)

1. Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. 19
2. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2015. J Natl Compr Canc Netw 2015; 13 (5): 554-86
3. Kuppers R. The biology of Hodgkins lymphoma. Nat Rev Cancer 2009; 9 (1): 15-27
4. Van Roosbroeck K, Cox L, Tousseyn T, et al. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 2011; 117 (15): 4056-64
5. Schwering I, Bräuninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003; 101 (4): 1505-12
6. Reichel J, Chadburn A, Rubinstein P, et al. Flow-sorting and exome sequencing reveals the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2014. [Epub ahead of print]
7. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99 (12): 4283-97
8. Cochet O, Frelin C, Peyron JF, Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal 2006; 18 (4): 449-55
9. Reichel J, Chadburn A, Rubinstein PG, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015; 125 (7): 1061-72
10. Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 2012; 3 (4): 209-25
11. Dutton A, Reynolds GM, Dawson CW, et al. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkins lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005; 205 (4): 498-506
12. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkins lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011; 29 (14): 1812-26
13. Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111 (6): 3220-4
14. Moreno BH, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J cancer 2015; Epub ahead of print
15. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24. 1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116 (17): 3268-77
16. Eichenauer DA, Engert A, Andre M, et al. Hodgkins lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl 3): 70-5
17. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-Term cause-specific mortality of patients treated for Hodgkins disease. J Clin Oncol 2003; 21 (18): 3431-9
18. Brusamolino E, Baio A, Orlandi E, et al. Long-Term events in adult patients with clinical stage IA-IIA nonbulky Hodgkins lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: A single-institution 15-year follow-up. Clin Cancer Res 2006; 12 (21): 6487-93
19. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109 (5): 1878-86
20. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-Term survivors of Hodgkins disease: A population-based evaluation over 25 years. J Clin Oncol 2002; 20 (16): 3484-94
21. Koontz MZ, Horning SJ, Balise R, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: The Stanford University experience over three generations of clinical trials. J Clin Oncol 2013; 31 (5): 592-8
22. van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 2015; 175 (6): 1007-17
23. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkins lymphoma: A collaborative British cohort study. J Clin Oncol 2011; 29 (31): 4096-104
24. Eichenauer DA, Thielen I, Haverkamp H, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group. Blood 2014; 123 (11): 1658-64
25. van der Kaaij MA, Heutte N, Meijnders P, et al. Premature ovarian failure and fertility in long-Term survivors of Hodgkins lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe dEtude des Lymphomes de lAdulte Cohort Study. J Clin Oncol 2012; 30 (3): 291-9
26. Behringer K, Mueller H, Goergen H, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013; 31 (2): 231-9
27. Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: An uncommon disease in need of study. Oncology (Williston Park) 2008; 22 (12): 1369-79
28. Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 2012; 119 (3): 692-5
29. Engert A, Ballova V, Haverkamp H, et al. Hodgkins lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkins Study Group. J Clin Oncol 2005; 23 (22): 5052-60
30. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011; 117 (16): 4208-17
31. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkins disease: results of a BNLI randomised trial. Lancet 1993; 341 (8852): 1051-4
32. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkins disease: A randomised trial. Lancet 2002; 359 (9323): 2065-71
33. Pfreundschuh MG, Rueffer U, Lathan B, et al. Dexa-BEAM in patients with Hodgkins disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkins Disease Study Group. J Clin Oncol 1994; 12 (3): 580-6
34. Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkins disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995; 13 (2): 396-402
35. Ribrag V, Nasr F, Bouhris JH, et al. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkins disease. Bone Marrow Transplant 1998; 21 (10): 969-74
36. Rodriguez J, Rodriguez MA, Fayad L, et al. ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkins disease. Blood 1999; 93 (11): 3632-6
37. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102 (4): 1458-65
38. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-Auristatin conjugates. J Biol Chem 2006; 281 (15): 10540-7
39. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363 (19): 1812-21
40. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012; 18 (1): 248-55
41. Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01712490
42. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkins lymphoma: A phase 1, open-label, dose-escalation study. Lancet Oncol 2013; 14 (13): 1348-56
43. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkins lymphoma. J Clin Oncol 2012; 30 (18): 2183-9
44. Rashidi A, Bartlett NL. Biologic Agents in the Management of Hodgkin Lymphoma. In: J Natl Compr Canc Netw. 2015 by the National Comprehensive Cancer Network 2015. 587-96
45. de Claro RA, McGinn K, Kwitkowski V, et al. US. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012; 18 (21): 5845-9
46. Chen RW, Palmer J, Martin P, et al. Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. Blood 2014; 124 (21): 501-1
47. Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma. Available form https://clinicaltrials.gov/ct2/show/NCT01508312
48. Moskowitz AJ, Schoder H, Yahalom J, et al. PET-Adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkins lymphoma: A non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015; 16 (3): 284-92
49. Moskowitz CH, Nadamanee A, Masszi T, et al. The AETHERA trial: results of a randomized, double-blind, placebo-controlled phase 3 study of brentuximab vedotin in the treatment of patients at risk of progression following autologous stem cell transplant for Hodgkin lymphoma. Blood 2014; 124 (21): 673-3
50. A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL). Available from: https://clinicaltrials.gov/ct2/show/NCT01716806
51. Peter Borchmann M, Dennis A, Eichenauer MD, et al. Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study. (. (Eds) American Society of Hematology, annual meeting; 2013. Abstract 4344
52. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8 (6): 467-77
53. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006; 203 (4): 883-95
54. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12 (4): 252-64
55. Sondak VK, Smalley KS, Kudchadkar R, et al. Ipilimumab. In: Nat Rev Drug Discov. England: 2011. 411-12
56. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015; Epub ahead of print
57. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkins Lymphoma. N Engl J Med 2014; Epub ahead of print
58. Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT01592370
59. Moskowitz CH, Ribrag V, Michot J-M, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). Blood 2014; 124 (21): 290-0
60. Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087). Available from: https://clinicaltrials.gov/ct2/show/NCT02453594
61. Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL. Available from: https://clinicaltrials.gov/ct2/show/NCT02362997
62. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003; 98 (2): 310-14
63. Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118 (19): 5119-25
64. Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85 (5): 320-4
65. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkins lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012; 30 (18): 2197-203
66. Meadows SA, Vega F, Kashishian A, et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012; 119 (8): 1897-900
67. INCB040093 and INCB040093 Combined With INCB039110 in Relapsed/Refractory Hodgkin Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02456675
68. Andres Forero-Torres PMB, Catherine S, Magid D, et al. A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). J Clin Oncol 2015; 33 (Suppl)): Abstract 8558
69. Forero-Torres A BP, Diefenbach CSM. A phase 1 study of pi3kδ inhibitor INCB040093 alone or in combination with selective jak1 inhibitor INCB039110 in patients with relapsed/refractory Hodgkin lymphoma. Ed.(Eds. 13th International Conference on Malignant Lymphoma; June 16-20 2015. Lugano, Switzerland: Abstract 107
70. LaCasce A, Bociek RG, Matous J, et al. Brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma who are relapsed or refractory after frontline therapy. Blood 2014; 124 (21): 293-3